{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT04161495_XTEND_1\\NCT04161495_XTEND_1_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set",
        "text": "The FAS will include all participants who are enrolled and receive at least one dose of BIVV001. Participants will be analyzed in the arm to which they were assigned.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The FAS will include all participants who are enrolled and receive at least one dose of BIVV001. Participants will be analyzed in the arm to which they were assigned.",
        "criteria": "Enrolled AND received >=1 dose of BIVV001"
      },
      {
        "id": "pop_2",
        "name": "Per-Protocol Set",
        "text": "The PPS will include all participants in the FAS who adhere to the protocol to a degree that their data are considered evaluable for the primary efficacy analysis. Criteria for exclusion from the PPS (e.g., major protocol deviations) will be finalized prior to database lock.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PPS",
        "populationDescription": "The PPS will include all participants in the FAS who adhere to the protocol to a degree that their data are considered evaluable for the primary efficacy analysis. Criteria for exclusion from the PPS (e.g., major protocol deviations) will be finalized prior to database lock.",
        "criteria": "FAS member AND no major protocol deviations"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set",
        "text": "The SAF will include all participants who receive at least one dose of BIVV001. Participants will be analyzed according to the treatment they actually received.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The SAF will include all participants who receive at least one dose of BIVV001. Participants will be analyzed according to the treatment they actually received.",
        "criteria": "Received >=1 dose of BIVV001"
      },
      {
        "id": "pop_4",
        "name": "Pharmacokinetic Analysis Set",
        "text": "The PKAS will include all participants who receive at least one dose of BIVV001 and have at least one evaluable PK sample.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PKAS",
        "populationDescription": "The PKAS will include all participants who receive at least one dose of BIVV001 and have at least one evaluable PK sample.",
        "criteria": "Received >=1 dose AND has >=1 evaluable PK sample"
      },
      {
        "id": "pop_5",
        "name": "Surgery Subgroup",
        "text": "Participants from any arm who undergo major surgery during the study will be included in the surgery subgroup to assess control and prevention of bleeding with BIVV001 treatment in the surgical setting.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Surgery",
        "populationDescription": "Participants from any arm who undergo major surgery during the study will be included in the surgery subgroup to assess control and prevention of bleeding with BIVV001 treatment in the surgical setting.",
        "criteria": "Undergo major surgery during the study"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at baseline in years"
      },
      {
        "id": "char_2",
        "name": "Endogenous FVIII activity",
        "code": "ENDOGENOUS_FVIII_ACT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Endogenous FVIII activity",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline endogenous FVIII activity level (severe defined as <1 IU/dL)"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 2
    }
  }
}